# Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension

Study · id `cardio:ct-nct01631227` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01631227](<https://clinicaltrials.gov/study/NCT01631227>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01631227

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 665 participants.

## Technical summary

Registry record NCT01631227. Randomized; quadruple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2013-04 (actual). Results posted on 2014-05-26.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 665 participants (enrolled count; ClinicalTrials.gov record NCT01631227, source copy `cardio:ctgov-nct01631227-2014-07-25`, retrieved 2026-10-26)
- Start date: 2012-06 (registry gives no type) (ClinicalTrials.gov record NCT01631227, source copy `cardio:ctgov-nct01631227-2014-07-25`, retrieved 2026-10-26)
- Primary completion: 2013-04 (actual) (ClinicalTrials.gov record NCT01631227, source copy `cardio:ctgov-nct01631227-2014-07-25`, retrieved 2026-10-26)
- Completion: 2013-04 (actual) (ClinicalTrials.gov record NCT01631227, source copy `cardio:ctgov-nct01631227-2014-07-25`, retrieved 2026-10-26)
- Results first posted: 2014-05-26 (ClinicalTrials.gov record NCT01631227, source copy `cardio:ctgov-nct01631227-2014-07-25`, retrieved 2026-10-26)
- Countries: Germany; Russia; United Kingdom (ClinicalTrials.gov record NCT01631227, source copy `cardio:ctgov-nct01631227-2014-07-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01631227-2014-07-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension
- Condition: Essential Hypertension
- Intervention (Drug): Eprosartan
- Intervention (Drug): Eprosartan Mesylate
- Intervention (Drug): Placebo Eprosartan mesylate
- Intervention (Drug): Placebo Eprosartan
- Lead sponsor: Abbott
- Lead sponsor class: INDUSTRY
- Collaborator: Quintiles, Inc.
- Collaborator class: INDUSTRY
- Collaborator: Synexus
- Collaborator class: OTHER
- Collaborator: author! et al. BV
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Abbott (`cardio:abbott`)

## Provenance

Content hash: 36ae24da9ea51654362bd034ebd9a4d9daa317f0a3ea87e80e0d0acab6f9acfe
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
